Company Of The Day: Pfizer

+19.98%
Upside
49.95
Market
59.93
Trefis
PFE: Pfizer logo
PFE
Pfizer

What?

Pfizer (NYSE:PFE) said that the U.S. FDA granted the company’s vaccine candidate targeted at respiratory syncytial virus PF-06928316 (RSVpreF) a Breakthrough Therapy designation.

Why?

Relevant Articles
  1. Should You Buy Pfizer Stock After An Upbeat Q2?
  2. Should You Buy Pfizer Stock Ahead of Its Q2 Results?
  3. Should You Buy, Sell, Or Hold Pfizer Stock At $52?
  4. Here’s A Better Pick Over FedEx Stock
  5. Company Of The Day: Pfizer
  6. What To Expect From Pfizer’s Q1?

The Breakthrough Therapy designation is meant to speed up the development and review process for treatments focused on serious or life-threatening conditions. The agency’s decision is based on a proof-of-concept Phase 2a study carried out by Pfizer.

So What?

The market for an RSV vaccine could be sizable, as there are currently no therapeutic or preventive options available for older adults with the disease. RSV is estimated to cause around 14,000 deaths in the U.S. every year.

See Our Complete Analysis For Pfizer

What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since the end of 2016.

 Returns Mar 2022
MTD [1]
2022
YTD [1]
2017-22
Total [2]
 PFE Return 12% -11% 62%
 S&P 500 Return 2% -7% 99%
 Trefis MS Portfolio Return 2% -9% 259%

[1] Month-to-date and year-to-date as of 3/25/2022
[2] Cumulative total returns since the end of 2016

Invest with Trefis Market Beating Portfolios

See all Trefis Price Estimates